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Abstract
Assessment of the role and investigation particularities (comparative and complementary 
aspects, hierarchies, preferential indication) adapted to the context of a global cardiovas-
cular (CV) evaluation, including clinical elements, non-invasive and invasive imagistic 
examination in order to estimate the cardiovascular risk (CVR) and to define the revas-
cularization therapeutic strategy in patients with critical leg ischemia (CLI). Complete 
and accessible evaluation involves accessible means of investigation like clinical exam, 
electrocardiogram, cardiac biomarkers, arterial, cardiac, and carotid ultrasonography 
which could be affordable in all cardiovascular departments. Non-invasive stress tests, 
coronary and arterial cervical angiography imaging leads in selected cases and where 
is possible to the identification of significant coronary and/or carotid lesions potential 
responsible for cardiac and cerebrovascular events after vascular surgery. The evaluation 
algorithm allows better risk stratification of patients with CLI in high and intermediate 
CVR. The “poly-arterial” status in patients with CLI changes the intervention manage-
ment with a more intensive pre-operative medical treatment, while the coronary and the 
carotid arteries revascularization might precedes the peripheral arterial revascularization 
procedures, in order to reduce the CV risk status.
Keywords: critical leg ischemia (CLI), cardiovascular risk (CVR), poly-arterial  
(multi-arterial sites lesions), perioperative evaluation, non-invasive stress tests,  
cardiac biomarkers
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1. Introduction
Atherosclerosis (ATS) is a systemic pathological process that affects coronary, cerebral and 
peripheral arterial circulation. Peripheral arterial disease (PAD) is a distinct athero-thrombotic 
syndrome marked by stenosis and occlusion of arterial beds [1]. A large proportion of PAD 
patients are not diagnosed before having a major ischemic cardiovascular (CV) event (MACE), 
which limits the use of medical therapies with recognized evidence of cardiovascular risk 
(CVR) reduction [2]. Even if claudication can remain stable over 10 years in 70–80% of patients, 
the prevalence of myocardial infarction (MI), stroke and CV death is high. PAD patients triple 
their risk of mortality from any other cause and have a six fold higher risk of death by coronary 
artery disease (CAD) than those without this ATS lesions. All these problems lead to repeated 
hospitalizations, low quality of life for patients and increased CV morbidity [3].
2. Predictors of perioperative cardiovascular risk
2.1. The risk of PAD patients in noncardiac vascular surgery
It is estimated that more than 200 million patients suffer a surgery intervention every year 
worldwide, and the proportion might increase up to 300 million in time. Most of these patients 
are elderly men, 25% of them having a high or intermediate CVR. The rate of MACE ranges 
from 11% in patients with one CV risk factor (CVRF) up to 33% in patients with four CVRFs. 
Perioperative mortality ranges from 0.9% in patients with one CVRF to 11% in patients with 
four CVRFs. Approximately 60% of patients with PAD have coronary artery disease (CAD), 
up to 25% of PAD patients have carotid-cerebrovascular atherosclerotic lesions, and the rate 
of MACE (MI, stroke and CV death) reaches 7% per year. The main causes of mortality in 
patients with PAD are due to cardiac events, coronary MI (60%) first of all, followed by major 
or fatal stroke (35%) and only a small proportion (15%) of these patients dies due to complica-
tions of critical peripheral arterial ischemia (by gangrene, septicemia and multiorgan failure) 
[4]. Along with coronary and/or cerebrovascular disease, the type of surgery is an independent 
predictive risk factor for death of PAD patients with multisite arterial lesions [5, 6]. This is 
why, patients undergoing vascular surgery have a higher risk of MI (31%), CV death (5%) than 
general surgery patients (3%) [4, 7, 8]. A good diagnostic and management strategy for PAD 
patients reduces vital CVR in terms of short outcomes and identifies patients with coronary 
and/or cervical arterial lesions at risk for long-term CV events. noninvasive tests can provide 
both diagnostic information (by revealing coronary ischemic heart disease (IHD) or cervical 
arterial lesions) and CVR prognosis in patients who undergo noncardiac surgery [4, 9, 10].
2.2. Benefits and limits of perioperative risk stratification
Cardiac risk stratification separates patients for vascular surgery into high-risk, interme-
diate and low-risk categories, adapting the management of perioperative therapy to their 
needs. Low-risk patients will be further investigated by completing noninvasive and inva-
sive tests, while for high-risk patients, perioperative management primordially changes. 
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The major objective of CVR stratification is the reduction of perioperative global morbidity 
and mortality. Clarifying the patient’s risk status allows the clinician as well as the sur-
geon to consent to a better informed patient. From a socio-economic point of view, reducing 
postoperative complications allowed to reduce perioperative care and treatment costs. The 
main impediment of perioperative risk stratification procedure is the duration, the cost and 
the number of investigational tests, which implicitly leads to postponing the intervention 
moment [4, 7, 8, 10]. And that could be done in elective surgery, but it seems to be quite 
difficult to be done in emergencies interventions.
2.3. Clinical elements of perioperative cardiovascular risk
2.3.1. Overview
Retrospective clinical studies have shown that a history of coronary artery bypass surgery 
(CABG), percutaneous transluminal coronary angioplasty intervention (PCI) or coronary 
angiography without significant lesions indicates a low risk for perioperative cardiac events. 
The risk is similar to that of patients without clinical signs of significant CAD. The term “pro-
tection” given by the presence of a coronary graft cannot be specified. Many studies in large 
groups of patients have shown the independent predictors of perioperative CVR: the history 
of MI, angina pectoris (AP), and ischemic ST-T changes on the electrocardiogram (ECG/EKG), 
as well as the clinical symptoms of congestive heart failure (HF) [9–11].
2.3.2. Several clinical risk assessment scores for postoperative cardiac events
The revised cardiac risk index (RCRI) is used by anesthesiologists and surgeons to assess the 
perioperative CVR in patients who undergo noncardiac surgery. Parameters included in the 
evaluation are age over 70 years, estimated risk of surgery, history or presence of IHD (MI 
or history of AP), congestive heart failure (HF), HT with signs of left ventricular hypertro-
phy (LVH), presence of Q waves or ischemic ST changes on resting electrocardiogram (ECG) 
cerebrovascular disease (CVD), the presence of DM (treated with insulin, additional risk) and 
renal failure (e.g., Table 1) [4, 12, 13]. The presence of more than one of these six independent 
predictors of cardiac complications following surgery is mandatory for further investigation. 
Patients who do not have active cardiac conditions are stratified into three groups by the 
RCRI: low (0 risk factor), intermediate (1–2 risk factors) and high (≥3 risk factors) [14, 15]. In a 
meta-analysis of 24 studies that reported the association of the RCRI with MACE or death in 
the hospital or within 30 days of surgery, the RCRI discriminated moderately well between 
patients at low versus high risk for cardiac events after mixed noncardiac surgery.
However, its performance was considerably diminished when it was used in patients who 
underwent vascular surgery and emphasized the necessity of development and validation 
of a suitable CRI for use in vascular surgery patients [14, 16, 17]. The American College of 
Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database derived 
from general and other specialty surgery patients have allowed the development of another 
risk model, in which five risk factors (basically the same from RCRI) were determined to 
be associated with MI/cardiac arrest following an operation [13]. In the VSG-RCI assess-
ment (published in 2010 by Vascular Study Group of New England (VSGNE), additional 
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risk factors were introduced: CVRF (increasing age, DM insulin-dependent, HT, smoking), 
clinical features (presence of aortic aneurysm, peripheral arterial ischemic symptoms, CAD, 
congestive HF, chronic obstructive pulmonary disease, elevated creatinine, abnormal cardiac 
stress test), previous CV medication administered (β-blockers long-term therapy, antiplate-
let, statins) and revascularization interventions (carotid endarterectomy, peripheral arterial 
bypass, endovascular/surgical interventions for aortic aneurysm). The RCRI predicted risk 
after carotid endarterectomy reasonably well, but substantially underestimated the other 
Clinical risk factors Clinical elements Active cardiac 
condition
Clinical presentation
History of ischemic heart 
disease (IHD)
Previous MI
Previous positive result 
on stress test
Use of nitroglycerin
Typical angina pectoris
ECG Q waves
Previous PCI or CABG
Unstable coronary
syndromes
Unstable or severe angina (CCS class 
III–IV)
Recent MI (7–30 days)
History of compensated 
previous congestive heart 
failure (HF)
Previous pulmonary 
edema
Third heart sound
Bilateral rales
Evidence of heart failure 
on chest radiograph
De-compensated 
HF
NYHA functional class IV
worsening or new-onset HF
History of cerebro-vascular 
disease (CVD)
Previous TIA disease
Previous stroke
Significant 
arrhythmias
High-grade atrioventricular block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias 
(including atrial fibrillation) with 
uncontrolled ventricular rate (HR 
> 100 bpm at rest)
Symptomatic bradycardia
Newly recognized ventricular 
tachycardia
Diabetes mellitus (DM) With or without 
preoperative insulin 
therapy
Severe valvular 
disease
Severe aortic stenosis (mean pressure 
gradient > 40 mm Hg, aortic valve 
area < 1.0 cm2 or symptomatic)
Symptomatic mitral stenosis 
(progressive dyspnea on exertion, 
exertional presyncope, or HF)
Renal failure Creatinine level > 2  
mg/dL
Adapted from [4, 13]. CCS, Canadian Cardiovascular Society; MI, myocardial infarction; HF, heart failure; NYHA, 
New York Heart Association; HR, heart rate.
Table 1. Clinical risk factor to predict MACE and active cardiac conditions to be evaluated and to be treated before 
noncardiac surgery.
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procedures for low- and higher-risk patients. VSG-CRI risk model predicted more accurately 
the risk of cardiac complications in vascular surgery patients than the RCRI, which under-
estimated in-hospital cardiac events in patients undergoing vascular surgery and that new 
VSGNE index was more accurate than the RCRI in predicting postoperative cardiac event. 
It should be noted that in this recent study only 45% of patients were evaluated by stress 
myocardial scintigraphy, the accessibility of the method still being limited [13, 18].
Generally, the type and the conditions of planned surgery cannot be fundamentally changed 
and can influence the postoperative CVR of patients. Urgent, prolonged (more than 5 h) and 
long hemodynamic stress (in major vascular interventions, intraabdominal and intrathoracic 
surgery) increase the risk of perioperative cardiac events. Peripheral vascular procedures pres-
ent the highest risk (13%); the incidence of postoperative CV events could reach 10–15% [4, 7, 19].
2.4. Noninvasive cardiovascular parameters (biomarkers, coronary artery 
calcification)
Cardiac biomarkers have been studied for years in prediction of CV long-term outcomes, but 
less so for preoperative prediction. The most important and evaluated four biomarkers tropo-
ninI (TNI), N-terminal brain natriuretic peptide (NT-BNP), cystatin C, and C-reactive protein 
(CRP) significantly affected the prediction of death from CV causes. The statistical significance 
increased when the four biomarkers were incorporated into a model with established risk fac-
tors [20]. From six risk markers of interest (coronary artery calcium (CAC), carotid intima-media 
thickness (IMT), ankle-brachial index (ABI), brachial flow-mediated dilation (BFMD), CRP and 
family history of CAD, at a median follow up of 7.6 years, the CAC (had the highest predic-
tive value), ABI, CRP and family history of CAD were independently associated with incident 
CAD [21, 22]. The addition of the degree of stenosis measured with computed tomography 
coronary angiography (CTCA), the presence of significant coronary artery stenosis (>50%) and/
or multivessel CAD in completion with the CAC value and the RCRI significantly improved 
the predictive model for postoperative CV events [23]. Addition of CTCA determines a slight 
improvement in discrimination for CV death or MI. When added to the RCRI, information 
from CTCA is five times more likely to overestimate risk in low-risk individuals than to iden-
tify a previously misclassified high-risk individual. Thus, current data do not support CTCA as 
a first-line preoperative screening test for CAD in PAD patients (e.g., Table 2) [4, 24].
High CRP levels are positively associated with PAD, independent of smoking, and multiple 
other cofounders, demonstrating the important role of inflammation in ATS. High levels of 
inflammatory markers would identify vascular surgery patients at increased risk for adverse 
events (graft failure, MACE) after lower extremity bypass surgery. Among patients with an 
elevated CRP (>5 mg/L) before surgery, major postoperative MACE occurred in 60%, com-
pared with a 32% rate in those with a baseline CRP < 5 mg/L (Table 2) [25].
High preoperative NT-BNP or CRP are independent predictors of perioperative MACE in 
noncardiac surgery; the addition of these two markers to the RCRI improves its predictive 
power for adverse events. There is a statistically significant association between an elevated 
preoperative NT-BNP level and various CV adverse outcomes within 30 days of surgery 
(composite of cardiac death, nonfatal MI and atrial fibrillation). NT-BNP concentrations 
of 99.5 pg./mL predicted cardiac events and 448 pg./mL predicted cardiac death (all-cause 
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mortality in the short-, intermediate- and long-term postoperative periods). Over the thresh-
old value of 448 pg./mL, NT-BNP had a positive predictive value of 100% and suggested that, 
if a preoperative NT-BNP level is in this vicinity, then it may be preferable to delay or cancel 
the procedure. Patients with high preintervention values of both CRP and NT-BNP are 10.6 
times more likely to experience MACE than patients with normal CRP and NT-BNP values. 
Patients with a postoperative BNP ≥245 pg./ml or NT-proBNP ≥718 pg./ml had a significantly 
elevated risk for 30-day CV mortality, nonfatal MI, and cardiac failure. In addition, these 
postoperative elevations are able to predict long-term outcomes (i.e. ≥ 180 days after surgery) 
(e.g., Table 2) [26, 27].
Similar to postoperative troponin (Tn) levels, the current data for postoperative BNP suggest 
that it is the absolute postoperative threshold, rather than the increase in the BNP between the 
preoperative and postoperative period, that is associated with postoperative morbidity and 
mortality. Natriuretic peptides act as a cumulative marker of myocardial damage sustained 
during the perioperative period, possibly as a result of ischemic injury, volume overload or 
both. However, it remains unclear what the exact temporal relationship between postopera-
tive BNP and Tn elevations is. In certain circumstances, it is possible that BNP elevation may 
precede Tn elevation, as may occur during fluid overload. In such cases, BNP elevations may 
identify patients at risk of subsequently developing myocardial injury and postoperative Tn 
elevation. Identification of patients at risk may provide a window for therapeutic interven-
tion. It is likely that the more common scenario is postoperative BNP elevation that occurs 
together with, or shortly after, a postoperative Tn elevation. In these cases, elevated postop-
erative BNP may reflect the severity of myocardial injury and may prognosticate short- and 
long-term outcomes (e.g., Table 2) [26, 27].
In the perioperative period, it is clear that any Tn elevation is associated with an increased risk 
of death, even in the absence of a defining features (e.g., ischemic symptoms and ECG changes, 
evidence of MI on echocardiography) necessary for the diagnosis of MI. Owing to the effects of 
anesthesia, and widespread use of narcotics, the majority of perioperative ischemic events are 
clinically silent. In the Perioperative Ischemic Evaluation (POISE) trial, 65% of patients with a 
perioperative ischemic event did not experience ischemic symptoms [28]. The risk of death at 
30 days was 9.7% in patients with a symptomatic MI and 12.5% in patients with an asymptom-
atic MI. Thus, the universal definition of MI may not be as sensitive in the perioperative period 
to detect ischemic events that are associated with poor, intermediate and long-term outcomes. 
Biomarker Indication Sensitivity Specificity
NT-BNP
CRP
TnT
Obtain preoperatively in high surgical risk patients scheduled to 
undergo non-emergent vascular surgery
75–88%
NA
97%
62–100%
NA
54%
CAC Evidence is currently lacking to recommend preoperative risk 
stratification with routine measurement
79% 61%
Adapted from [13].
Table 2. Indications and characteristics of various markers in preoperative cardiac risk stratification.
Peripheral Arterial Disease - A Practical Approach54
An isolated peak cardiac biomarker elevation (preferably Tn) with or without correlation with 
ischemia may be the most sensitive tool to detect perioperative ischemic events that are clini-
cally important [29]. A peak postoperative TnT (>0.02 ng/ml) measured within the first 3 days 
after surgery is the strongest predictor of 30 days mortality and explained 41.8% of the deaths 
in population [30]. The current data suggest that the absolute postoperative threshold of Tn 
is a stronger independent predictor of postoperative MI and intermediate-term survival than 
the increase in the Tn level between the preoperative and postoperative period. Current data 
therefore suggest that a raised preoperative Tn level may identify patients who are at risk of 
increased short-term CV morbidity, mortality and long-term mortality (1 year after surgery, 
but no longer) due to his high sensitivity, but it may be an inappropriate additional test for 
improving preoperative risk stratification due to its poor specificity (Table 2) [26].
Preoperative cardiac biomarkers (especially BNP and Tn) evaluation adds incremental value 
to the risk stratification (by RCRI) for MACE (i.e. MI, pulmonary edema, CV death) and for 
in-hospital mortality [26]. While the body of evidence for the use of cardiac biomarkers for risk 
stratification is not extensive, the utility of assessing certain biomarkers in high-risk vascular 
surgical patients is suggested. A pharma-economic analysis of routine Tn surveillance in all 
patients who fulfilled the VISION study, based on a 25% relative risk reduction for vascular 
mortality and perioperative MI following the introduction of statin and aspirin therapy in high-
risk patients who were Tn positive, found routine Tn surveillance to be cost-effective [30, 31].
2.5. Cardiac evaluation
2.5.1. Investigation of inducible myocardial ischemia
An ECG should be obtained in all moderate to high-risk vascular surgery patients and confers 
well-accepted prognostic information [11]. The two most common forms of stress testing are 
exercise ECG (not often feasible due to debility of many vascular surgery patients) and exer-
cise or pharmacologic stress testing combined with imaging (e.g. dobutamine/dipyridamole 
stress echocardiography (DSE) and myocardial perfusion imaging scintigraphy (MPI)). There 
is an association between a positive test (ST depression) and the likelihood of postoperative 
cardiac complications [15]. Outpatient ECG monitoring is relatively affordable, but requires 
manual interpretation from the investigator, being time-consuming. The automatic or man-
ual interpretation of the ischemic score depends on the correctness and the accuracy of the 
recorded ECG path. At a very variable percentage of patients (12–73%), recording irregu-
larities are an obstacle to correct interpretation [32]. A study involving both noncardiac (gen-
eral and vascular) surgery patients has not shown benefits in performing this type of ECG 
screening in preoperative monitoring [33]. Other studies focused only on patient groups in 
vascular surgery demonstrated both the positive and negative predictive value of the results 
of ECG monitoring of silent ischemia, but under the significance of the values provided by 
MPI. However, the combination of the two tests does not increase the predictive value [7, 28]. 
Ischemia and/or intra- and postintervention endocardial lesions (T-negative or ST-segment 
elevation) are more predictive for perioperative cardiac events (up to 85% of perioperative 
MI may also be preceded by episodes of ischemia-lesion on ECG), and the prognostic value 
increases if the cardiac Tn serum level reaction is associated [7].
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2.5.2. Noninvasive clinical imaging tests for cardiac perioperative risk assessment
The American College of Cardiology (ACC) and the American Heart Association (AHA) as 
well as European Society of Cardiology (ESC) introduced guidelines to detect and manage 
perioperative cardiac risk and to prevent cardiac complications after vascular surgery [15, 19]. 
For preoperative noninvasive stress testing (NIST), the guidelines recommended that patients 
with active cardiac conditions should be evaluated and treated. NIST may be considered for 
patients with high or intermediate risk, if it will change management.
NIST include left ventricular (LV) function evaluation and inducible myocardial ischemia 
through ECG holter monitoring, ECG, echocardiography or scintigraphy coupled with exer-
cise trial or pharmacological stress methods (Table 3). These noninvasive assessment tests 
should be able to detect cardiac abnormalities not revealed by clinical scores. The simple 
observation of some cardiac abnormalities does not necessarily means augmenting periopera-
tive cardiac risk [32, 33].
NIST requires logistical and financial support. The PAD patients have less accessibility to MPI 
when compared to CAD patients. The interpretation of the investigation results in these stud-
ies is quite variable, which decreases the predictive accuracy. The explanations of these vari-
able interpretations could be related to differences between the definition of fixed objectives, 
the follow-up strategies and the heterogeneity of the evaluated groups. Even though NIST 
are available and can be performed, they do not provide a “guarantee” for the perioperative 
period, as long as postoperative events have multifactorial causes that could not be accurately 
predicted [32, 33].
The perioperative period is characterized by myocardial ischemia due to hypercoagulabil-
ity, increased consumption and oxygen demand, caused by catecholamine discharges, pain, 
Tests Prerequisites Recommended indications
Electrocardiogram (ECG) None in prior 3 months
Perioperative risk death/MI >1%
CAD, PAD, CVD
Significant arrhythmia
Structural heart disease
Document baseline*
Echocardiogram Potential to change management
Not for prognosis or as surrogate for 
exercise capacity
HF with worsening symptoms
Dyspnea of unknown origin
Clinical suspicion of structural heart disease
HF or structural heart disease and no prior test 
within 1 year*
Non-invasive stress test 
(NIST)
Perioperative risk death/MI >1%
Elevated risk or known CAD
Potential to change management
Unable to perform >4 METs based on subjective 
assessment or validated tool
Adapted from [15].*Uncertain utility may be considered. CAD indicates coronary artery disease; CVD, cerebrovascular 
disease; HF, heart failure; MET, metabolic equivalents; PAD, peripheral arterial disease.
Table 3. Recommendations for preoperative cardiac investigations in vascular surgery.
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anemia, anesthetic and surgical stress. Noninvasive clinical screening (via ECG, cardiac, 
carotid-vertebral and peripheral arterial ultrasound and where possible by NIST) coupled 
with cardiac Tn serum levels dosing increases the safety of postoperative evolution and 
improves the prognosis [34, 35].
Although available in many cardiology centers, stress tests could not be performed systemati-
cally in all presurgery intervention patients. Due to the pain caused by critical leg ischemia 
(CLI), 30–70% of PAD patients could not perform the exercise test; they are added to those 
who could not do it the same because of obesity, degenerative diseases of the hip and knee or 
postvascular sequelae. In this context, the results of the effort tests were inconclusive in sev-
eral studies [7, 36]. For these patients, stress tests using pharmacological agents that increase 
consumption and demand for oxygen represent an alternative for detecting coronary isch-
emia. These stress tests are dipyridamole-coupled ECG, thallium myocardial scintigraphy 
and echocardiography coupled with dobutamine or dipyridamole. The presence of “revers-
ible” segmental infiltration defects fixation, or alterations in segmental parietal kinetics has 
a predictive sensitivity with positive value greater than the presence of “fixed” defects (e.g., 
Table 4) [28].
Stress echocardiography with dobutamine (DSE) (or dipyridamole) has the theoretical advan-
tage for evaluating both segmental ventricular parietal kinetics and altered LVF as determined 
by inducible myocardial ischemia. Most echocardiography stress studies conducted on vascu-
lar surgery patients suggested that DSE had a good negative predictive value, but the positive 
Non-invasive stress 
tests
Advantages Disadvantages
Stress ECG Most affordable of the common testing modalities
Widely available
Unable to use in many vascular surgery 
patients that suffer from claudication and 
poor functional capacity, as target heart 
rates cannot be achieved. No additional 
information about cardiac function that 
can be seen with cardiac imaging is 
provided
Stress echo-
cardiography 
(dobutamine) DSE
If pharmacologic stress testing is necessary, may be 
preferred in patients with known bronchospastic 
lung disease or significant carotid stenosis. 
Preferable choice when any additional information 
about left ventricular function and/or valvular heart 
disease is desired. Shorter testing time with results 
available sooner. No ionizing radiation.
Dobutamine has the ability to induce 
arrhythmias and increases in blood 
pressure and/or myocardial contractility; 
avoid in patients with known 
arrhythmias and symptomatic or large 
aortic aneurysms
Myocardial 
perfusion imaging 
or scintigraphy (MPI 
with dipyridamole/
thallium)
If pharmacologic stress testing is necessary, may be 
preferred in patients with known arrhythmias and 
symptomatic or large aortic aneurysms. Preferable 
for the assessment of myocardial viability in 
patients with known left ventricular dysfunction, 
where the extent and severity of inducible ischemia 
is of importance.
Dipyridamole may induce bronchospasm 
or decreases in blood pressure; avoid in 
patients with bronchospastic lung disease 
or significant carotid stenosis. Longer 
testing time and delay for results to be 
available. Ionizing radiation. Failure to 
detect global ischemia
Adapted from [13].
Table 4. Comparison of noninvasive stress testing modalities.
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predictive value was moderate. This does not increase the discriminatory value of the clinical 
criteria and does not change the appropriate risk group ranking after the RCRI score. In patients 
with one or two positive cardiac markers, the negative value of DSE was confirmed by the 
absence of postoperative cardiac events, while a positive result was followed by an incidence 
of up to 5% of cardiac events postoperative (MI, sudden death), so preoperative DSE offered 
no incremental value for determining postoperative adverse cardiac outcomes [7, 28, 37]. The 
second multicenter Dutch Echocardiographic Cardiac Risk Evaluation study showed no dif-
ference between the intermediate risk patients with positive NIST results group and negative 
results group in cardiac death or MI at 30 days after surgery (1.8 vs. 2.3%) (e.g., Table 4) [38].
Myocardial perfusion imaging (MPI) scintigraphy combined with pharmacokinetic stress 
test and EKG with dipyridamole are most used today in centers that benefit from this avail-
ability. Despite the initial expectations of better characterization and stratification of patients, 
especially from groups initially assessed as having intermediate or low risk for postopera-
tive cardiac events, the results were not what they expected. Stress MPI has a relatively high 
sensitivity for the prediction of cardiac complications, but the specificity of this method is less 
satisfactory. Preoperative MPI has a high negative predictive value, but it has not proven to 
be sufficiently sensitive, and the benefit of MPI was unproven in low-risk patients and prob-
ably not cost-effective. There was no association between reversible defects on dipyridamole 
stress MPI and adverse cardiac events in moderate-risk patients undergoing elective vascular 
surgery. Based on the scintigraphy results, previously patients in the low-risk group switched 
to the intermediate risk group, but the rate of postsurgery intervention cardiac events do not 
change significantly, indicating the limited positive predictive value of these tests and prov-
ing no independent prognostic value superior to clinically stratified risk [7, 28]. Information 
about myocardial perfusion does not accurately predict adverse cardiac outcomes (e.g., as 
prolonged myocardial ischemia, MI, congestive HF and severe ventricular tachyarrhythmia) 
following univariate and multivariate analyses. The best correlates of cardiac complications 
were documented evidence of CAD and age greater than 65 years (e.g., Table 4) [12, 24, 39].
Two important questions remain unanswered related to the patient at risk: which stress test 
is best for which patient and what interventions outside of best medical management are of 
benefit to reducing perioperative ischemia events. No large head-to-head analyses of DSE 
versus MPI have been performed, although two well-known meta-analyses have compared 
the different modalities. DSE showed a positive trend toward better diagnostic performance 
than the other tests. Relative to MPI, DSE had a similar sensitivity, but significantly greater 
specificity (70% vs. 49%) (e.g., Table 3). Comparison with summary receiver operating char-
acteristic analysis between all modalities revealed a trend toward better performance with 
DSE, but this was only significant when compared with MPI. DSE has better negative pre-
dictive value characteristics than MPI. In addition, a moderate-to-large perfusion defect by 
either DSE or MPI predicts postoperative MI and death, but DSE is slightly superior to MPI 
in predicting postoperative cardiac events [24, 39].
A typical pattern has emerged with stress testing for risk stratification prior to surgery; the 
positive predictive value is usually very low, and the negative predictive value is typically 
high. Routine preoperative NIST is not necessary in all patients undergoing revascularization 
for CLI, especially for patients in the low-risk group and for those undergoing endovascular 
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treatment [40]. Widespread use of NIST in assessing the risk of perioperative CV complica-
tions remains controversial due to the low predictive value that affects the accuracy of the 
information. Therefore, the implications for CV risk stratification remain unclear. Even with 
the reported subtle differences between MPI and DSE, the fact remains that current guidelines 
do not distinguish between one or the other NIST for the preoperative workup of surgical 
patients. In line with current joint guidelines, we would recommend that surgeons take into 
account the availability and expertise in interpretation of the varying modalities and patients 
specifics at their respective institutions when deciding which test to obtain (e.g., Figure 1) 
[13]. A reversible defect on NIST is considered a predictor of postoperative MACE, and pos-
sible revascularization might be recommended. Some authors have suggested coronary angi-
ography as a routine screening test, due to the significant prevalence of coronary involvement 
in vascular patients. Because coronary angiography is an invasive method with a risk of up to 
0.05%, it was not used in studies as a routine examination in perioperative RCV assessment 
in noncardiac surgery patients. Last data suggested perioperative MI is quite common in 
Figure 1. Suggested algorithm for preoperative optimization in vascular surgical patients. AP—Antiplatelet therapy; 
HTN—Hypertension. Adapted from [13].
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nonvascular surgical patients, vascular patients being relatively protected by cardiovascular 
medication previously administered, and that postoperative events such as anemia play a 
major role in postoperative MI [41].
2.5.3. Cardiac ultrasound evaluation in perioperative assessment of PAD patients
With cardiac ultrasound (US) (or echocardiography), we can evaluate both the function and 
the morphology of the heart. The presence of LVH is associated with an increased risk of 
CV morbidity and all-cause mortality, which emphasizes the importance of diagnosis. The 
quantitative evaluation of the LV systolic function by LV ejection fraction (LVEF) is a simple 
and specific predictive index in relation to clinical utility [42]. End-systolic LV volume is an 
independent predictor of survival in CAD and LVEF has prognostic value for survival in post-
MI patients. The presence of diastolic dysfunction represents an early indicator of LV function 
impairment. Although that high mortality of PAD patients was mainly attributable to coexist-
ing coronary or cervical arteries disease, the prevalence of US abnormalities in patients with 
peripheral arterial ischemia was not systematically studied. Asymptomatic LV dysfunction 
is predictive for short- and long-term perioperative CV events in vascular surgery patients; 
therefore, the echocardiogram should be routinely performed in surgical patients for stratifi-
cation of CV risk, even in the absence of HF symptoms [43].
The prevalence of CVRF (smoking, DM, dyslipidemia, HT) in PAD patients causes, in addition 
to peripheral arterial lesions, coronary arteries and myocardial involvement with ischemic, 
hypertensive and/or diabetic heart disease, aortic and mitral valve calcifications and sometimes 
myophatic evolution through dilated cardiac disease [44–46]. In PAD patients were found high 
prevalence of clinically significant cardiac US changes (61.6% vs. 35.3%), especially related 
to the LV dysfunction and the presence of aortic stenosis (AS) compared to patients without 
PAD. The presence of PAD is shown to be an independent predictor of LVEF <50%. In PAD 
patients, MI and HF are the main causes of mortality [47]. PAD patients develop a significantly 
higher degree of LVH compared with patients with the same means BP but with no PAD. By 
cardiac US examination, LVH was found in 75% of patients with HT, CAD and PAD and in 
46% of patients with HT and CAD but without PAD, respectively. LVH was found in 93% of 
PAD patients, with ABI <0.6, and 62% of patients with ABI between 0.6 and 0.9 [43, 47–49]. PAD 
patients with CLI have higher CV morbidity than stable PAD patients. US evaluation is useful 
in defining the group of patients with low CV risk, in which can be performed with relative 
safety the revascularization of the limb by interventional/surgery procedures. In the case of the 
intermediate risk group, additional CV risk assessment tests are required [44–50].
2.6. Perioperative cardiac management strategies
2.6.1. The impact of perioperative risk stratification in the management of PAD patients
Approximately 10% of general surgery patients are included in the high-risk surgical periop-
erative group after the standard clinical and noninvasive assessment. But for vascular surgery 
patients, the percentage of high-risk patients may increase by 10–20%. From these, 5–10% may 
be eligible for myocardial revascularization (PCI or CABG) [7]. In vascular surgery patients in 
intermediate or low perioperative risk groups, it is advisable to perform NIST. It is possible, 
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however, that NIST does not provide additional predictive perioperative risk elements. Also, 
these tests do not provide information about cerebrovascular ischemic risk, derived from cer-
vical arterial lesions, almost equally founded as coronary involvement in vascular surgery 
patients [7, 29]. Clinical judgment is important in assessing the balance between the relative 
urgency of identified cardiac and noncardiac surgery problems. A relatively small proportion 
of surgical patients require urgent preoperative treatment of cardiac conditions: congestive 
HF, life-threatening arrhythmias or acute coronary syndrome (ACS) (recent MI with signifi-
cant evidence of ischemic risk or unstable, severe AP). However, there are situations in which 
the surgical situation with an important vital risk imposes the operative decision, even under 
an incomplete cardiac evaluation [7, 29].
2.6.2. Impact of coronary revascularization decision on noncardiac surgery patients
Patients in noncardiac surgery are at risk of major perioperative cardiac events (sudden 
cardiac death, cardiorespiratory arrest, MI). In these patients, the in hospital mortality rate 
is among 15–25%. Patients who underwent a postsurgery intervention cardiac arrest have a 
mortality rate in the hospital up to 65% and represent a risk factor for cardiac death within 
the next 5 years postoperatively. Perioperative MI is an independent risk factor for the risk 
of CVD and the increase incidence of a new MI over the next 6 months postoperatively [7]. 
This is why the concern is both for the most discriminatory assessment of noncardiac surgery 
patients in different risk groups, as well as for finding the best prevention strategies (interven-
tional, medical, etc.) for perioperative CV events. By preoperative coronary angiography, the 
prevalence of CAD ranged between 50 and 80% and is dependent on the specific distribution 
of the PAD. It is also clear that periprocedural myocardial ischemia, even non-ST segment MI 
and Tn leaks, confer a significant 26–55% decreased survival through 5 years, supporting the 
impetus for careful patient preparation [13].
In retrospective studies, for both vascular and nonvascular surgery patients, the “protective” 
effects of coronary revascularization in reducing perioperative MACE were controversial [7]. 
“Prophylactic” preoperative myocardial revascularization of significant lesions could reduce 
perioperative coronary complications in patients with unstable CAD (ACS) and high CVR. There 
is a significant difference in mortality among high CVR patients who underwent coronary 
revascularization prior to noncardiac surgery (0.9%) compared to high CVR patients who did 
not undergo coronary revascularization procedures (2.4%) [7]. Coronary revascularization per-
formed prior to noncardiac surgery has as a primary objective the reduction of CV mortality in 
the long-term outcome and as a secondary objective, the reduction of CVR in patients with high 
coronary risk: unstable refractory AP, left main coronary artery stenosis, coronary multivessel 
significant lesions, including anterior descendent artery (ADA) and altered LV systolic func-
tion. Patients who underwent myocardial revascularization before noncardiac surgery had a 
lower rate of long-term postoperative cardiac events (up to 5 years after noncardiac surgery). 
The lowest incidence of CV events in long-term outcome after noncardiac vascular surgery was 
observed in the group of patients with PCI versus revascularized patients by CABG [50, 51].
The Coronary Artery Revascularization Prophylaxis (CARP) trial showed no difference in 
the rate of postoperative MI (defined by elevated Tn level) (12 vs. 14%) in 30-day mortality, 
and MACE and mortality at 2.7 years (22 vs. 23%) in patients scheduled for vascular surgery 
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with coronary artery revascularization before surgery compared with patients with no revas-
cularization before surgery, but there was a statistically significant survival benefit at 4 years 
(87% vs. 70%) that persisted up to 8 years. The CARP trial focused on patients who had stable 
CAD and those without left main coronary disease or significant valvular heart disease. Time 
to vascular surgery was significantly longer in the revascularization group [52, 53]. Although 
this evidence is encouraging, caution is warranted. Of note, excellent adherence with cardio-
protective drugs was documented. At least one large database review of nonvascular surgical 
patients concluded opposite findings, suggesting a benefit of revascularization, so the contro-
versy remains open [54].
A prospective study included patients evaluated before vascular surgery by MPI to complete 
the coronary angiography indication followed by myocardial revascularization by PCI and/
or CABG. The results of MPI have increased the rate of coronary revascularization from 4.1% 
to 14.7%, without significantly improving postoperative MACE (MI, sudden cardiac death 
in the first 30 days after surgery intervention). However, it should be noted that the patients 
included in the study had one or two coronary vessels significant lesions with preserved 
LV systolic function and with optimal medical therapy. Patients with CAD and with severe 
impairment of LV systolic function, unstable AP and AS were not included. In vascular sur-
gery patients having three coronary vessels significant lesions, there was a slight decrease in 
the incidence of perioperative cardiac events in myocardial revascularized patients before 
vascular surgery (43%) versus those treated by standard medical therapy (33%) [7]. Therefore 
in the coronary revascularization decision made prior to noncardiac surgery, three elements 
should be considered: the coronary risk of the patient, the risk of bypass surgery and the risk 
of noncardiac surgery. These results do not suggest that there are benefits in prophylactic 
coronary revascularization in patients with stable CAD regarding the short-term evolution 
after vascular surgery intervention [50, 51].
One of the main objectives of preoperative cardiac evaluation should be the identification of 
patients with high-risk coronary anatomy, amenable to revascularization, by an appropriate 
and discriminatory noninvasive/invasive cardiac evaluation. Once identified, the next ques-
tion that needs to be answered is what the best revascularization strategy would be, CABG 
or PCI? The indication and the accomplishment of PCI before noncardiac vascular surgery 
are directed toward patients with high coronary risk prior to noncardiac surgery. PCI has 
the advantage of a low periprocedural risk (0.01%) and avoids the stress of CABG. The dis-
advantage of the PCI is that some lesions could not be accessed by angioplasty and should 
be resolved later by CABG [7, 50, 51]. Long-term outcomes appear to be better in patients 
undergoing CABG when compared to PCI, but incomplete revascularization after PCI, 
impact of stent-related complications and progressive occlusive CAD should be considered 
while evaluating the disadvantages of PCI over CABG. The heightened thrombogenic poten-
tial of newly implanted stents and prothrombotic state induced by the surgical stress increase 
the risk of in stent thrombosis. Premature discontinuation of antiplatelet therapy in patients 
with bare metal stents (BMS) or drug eluting stent (DES) is associated with a high rate of 
stent thrombosis and perioperative mortality. Elective surgical procedures that carry a poten-
tial for increased perioperative bleeding should be postponed until a minimum course of 
dual antiplatelet therapy (DAPT) has been completed. In patients presenting for emergency 
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noncardiac surgery after stenting, consideration should be given to the risk of interrupting 
thienopyridine antiplatelet therapy compared with the risk of bleeding from surgical proce-
dures, to continuation of aspirin in the perioperative period and to restarting thienopyridine 
as soon as possible [4].
Coronary revascularization is not recommended before surgery for patients with stable CAD 
in both ACC/AHA and ESC guidelines for the management in patients undergoing noncardiac 
surgery and it is recommended only in circumstances where it would be indicated even in the 
nonoperative setting. In general, CABG is recommended for left main disease, triple-vessel 
disease, complex anatomy or high-risk comorbidities (e.g. diabetes). Given the uncertain ben-
efits of preoperative PCI for improving outcome after noncardiac surgery, current guidelines 
suggest consideration of PCI only for patients with left main disease whose comorbidities 
preclude CABG and for patients with unstable CAD (e.g. ST-elevation MI, non-ST-elevation 
ACS) who are appropriate candidates for emergency or urgent revascularization. If revascu-
larization by PCI is considered, BMS is preferred over DES for vascular surgery patients given 
the time pressure to proceed with vascular surgery [15, 19].
The additional risk of anesthesia and intervention stress in noncardiac surgery patients who 
also have simultaneous cardiac problems should be noted. Even under these conditions, 
the idea of “prophylactic” coronary revascularization, in all cases, could not be accredited 
to patients who undergo vascular surgery, on the premises that they have multisite arterial 
lesions and therefore they also have coronary ATS [36]. Probably only prophylactic coronary 
revascularization of significant lesions in confirmed CAD could prevent perioperative com-
plications in noncardiac surgery patients [8].
In the Reduction of Atherothrombosis for Continued Health (REACH) Registry, more than 
50% of PAD patients had a concomitant CAD [2]. This means that modification of ATS risk 
factors is important in the long term and perioperative CVR is high in the short term [55]. 
Patients with high CVR should benefit from a sustained medical treatment and control of 
CVRF, considering the context of a possible myocardial revascularization intervention by 
PCI or by CABG, as well as the perspective of a future vascular surgery. Patients at risk of 
having CAD (regardless of the risk group) should be given control of blood pressure, serum 
cholesterol (via statins), cardiac compensation (angiotensin converting enzyme inhibitors 
(ACEI), diuretics) and arrhythmia (β-blockers, amiodarone). Numerous scientific studies 
have demonstrated the beneficial role of β-blockers, antiplatelets, ACEI and statins in reduc-
ing perioperative CV mortality in patients undergoing noncardiac vascular surgery. Statins 
and antiplatelet therapies are also involved in ATS plaque stabilization and improvement of 
endothelial dysfunction [56–58].
2.7. Cervical arterial ultrasound evaluation in perioperative assessment of PAD 
patients
With the increase in the use of cardiac and arterial ultrasound (US) in assessing the patient 
with suspected or known PAD, the diagnostic and prognostic accuracy of these explorations 
has increased, the sensitivity and specificity of US detection cervical arterial lesions may reach 
95%. Noninvasive US methods can also be applied to a wide range of patients including those 
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at high risk for myocardial stress testing. With respect to CVD, a history should ascertain any 
previous stroke or transient ischemic attack, as well as detail the associated presentation and 
deficits. It is important to document the etiology to distinguish ATS carotid stenosis from 
cardio-embolic disease [44].
Carotid intima media thickness (IMT) measured by US is a noninvasive predictive marker 
independent of the onset, progression and extension of ATS disease, demonstrated in numer-
ous studies. The increase in carotid IMT is associated with a higher incidence of coronary 
events and multisite ATS lesions [59]. Increased IMT has common risk factors with the onset 
and progression of coronary and cerebrovascular ATS lesions (HT, DM, dyslipidemia, smok-
ing) [60, 61]. Furthermore, increased IMT demonstrates good reproducibility for both the 
progression and regression of ATS disease and has been validated as a vascular marker of 
ATS evolution in numerous clinical trials. At the same time, invasive studies have shown that 
treating CVRF for CAD can also significantly reduce progression of IMT [62, 63]. Carotid 
and femoral IMT thickening are associated with the presence of CVRF; the occurrence of CV 
events is an indicator of the presence of PAD. It has been shown that these risk factors and CV 
events are significantly linked to increased carotid and femoral IMT. The treatment of CVRF 
is associated with a decrease in the progression of IMT thickening, parallel to the reduction 
of CV events and an improvement in the symptoms associated with PAD. This finding is 
particularly evident in the context of hypolipemiant therapy. IMT, as an additional predictor 
of CVR, may influence the decision of therapeutic intervention by medication [59–63].
Significantly elevated IMT values were seen in PAD patients at femoral artery, simultaneous 
with carotid artery, which allowed the conclusion that the presence of PAD is associated with 
morphological alterations and dynamic variations of both the femoral and the carotid artery 
walls. DM patients with PAD had a significantly higher IMT at the carotid bifurcation and at 
the distal common carotid artery, relative to those without PAD. Thus, carotid IMT may be a 
marker of ATS with different localizations in patients with type 2 DM and reflects morphologi-
cal and hemodynamic similarities between arterial beds [64]. Today, IMT is one of the most 
commonly used parameters of noninvasive assessment of CV-ATS risk. In the initial stages, 
clinical latency of ATS, the increase of carotid IMT over normal value, often is an indicator of 
the asymptomatic arterial ATS lesions as well as an accompanied predictor for the increased 
risk of future CV events in already symptomatic arterial ATS territories [1, 65]. The amount 
of carotid IMT in PAD patients is correlated with body mass index (BMI), ABI, serum LDL-
cholesterol and the number of arterial cervical ATS plaques. These results support the hypoth-
esis that ATS is a systemic, generalized disease, leading to functional and structural changes in 
each of the segments of the arterial system, as confirmed by many other studies that described 
the concomitant occurrence of carotid, coronary and peripheral arterial ATS disease. Up to 81% 
of PAD patients with increased IMT had angiographic coronary artery lesions, while 57% had 
carotid ATS plaques. Therefore, there is a statistically significant correlation between increased 
carotid IMT and the severity of CAD and also the presence of carotid ATS plaques and PAD 
clinically manifested which are positive predictive factors for the presence of CAD [1, 65].
PAD patients had advanced cervical arterial ATS lesions expressed both by a higher IMT 
and an increased prevalence of ATS plaques. Stenotic and occlusive ATS is a systemic phe-
nomenon commonly coexisting in several arterial territories (coronary, carotid, peripheral 
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arteries), often symptomatic in one of the arterial areas and asymptomatic in other affected 
arterial areas [44–46]. There are fewer studies that investigated the lesions in the cervical arte-
rial system in patients with PAD, compared to the large number of studies investigating the 
coronary-carotid relationship [65]. Noninvasive vascular imaging, especially CV ultrasound, 
plays a particularly important role in the carotid evaluation system, and in some aspects (the 
morphological characterization of the ATS lesion and the possibility of analysis in multiple 
“nonstandardized” incidences) is superior to conventional angiography allowing accurate 
measurement of the functional diameter and the lumen area of the vessel, precise localization 
and dimension (thickness/length/extension and volume) of the ATS plaque, the ecostructure 
and the surface characterization of the ATS plaque and defining the type of vascular remodel-
ing. Thickness, ecogenicity and endoluminal surface of the ATS plaque are the first features 
related to a possible instability characterized by the US assessment of vascular lesions [67, 68].
There are studies that argue that US technique overestimates the severity of carotid stenosis 
compared to angiographic assessment, but these results depend on the US way of quantifying 
stenosis. The two-dimensional US combined with color and pulse doppler modules generally 
leads to superimposable results with angiographic quantification [68–71]. Carotid angiogra-
phy is indicated in selected cases and, particularly in cases where US is difficult to perform 
and poses diagnosis problems, shows particular aspects or atypical pathological pathways. 
Angiography visualizes intracranial circulation, not quite accessible to extracranial US (even 
transcranial doppler), which delivers indirect and segmental information related to cerebral 
circulation, which may present morphological and trajectory abnormalities. Information on 
the patency of intracranial collateral supply is important in the prognosis of carotid occlusion. 
Carotid angiography, in this case, helps to diagnose a possible subocclusive carotid stenosis, 
which would make the patient a candidate for a probably invasive solution [44–46, 66–71].
3. Conclusions
Patients with PAD undergoing elective vascular surgery have a high prevalence of coronary 
and cerebrovascular ATS with associated comorbidities (DM, renal failure, anemia) and are 
at an increased risk of perioperative death and MACE (MI or stroke). The management of 
patients with PAD refered to high-risk vascular surgical procedure for intermittent claudica-
tion, CLI or expanding abdominal aortic aneurysm requires risk stratification, optimization 
of medical therapies and limited use of cardiac imaging prior to surgery. Preventive coronary 
revascularization in patients with stable CAD, prior to the vascular operation, with the sole 
intention of mitigating the risk of CV complications in the perioperative period, is not effec-
tive and may be associated with significant bleeding and thrombotic risks, in particular, if 
stents are used. The patient, surgeon and anesthesiologist can be initially informed about 
the risk of surgery using modern preoperative risk indices (RCRI, NSQIP, VSG-CRI calcula-
tor). Modern biomarkers, such as BNP and high-sensitivity Tn assays, are likely to play a 
more substantial role in preoperative assessment in the future, but for now they are indicated 
for high-risk patients. A strategy of universal use of cardiac Tn in the perioperative period 
for active surveillance of myocardial ischemia may be more reasonable and cost-effective 
than the current standard of care and widespread use of cardiac imaging prior to high-risk 
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surgery. An elevated cardiac Tn after vascular surgery is recommended and predictive to 
detect perioperative ischemic events associated with a long-term mortality risk. If the car-
diac biomarkers are negative and medical therapy is thought optimized, proceeding with 
the surgery seems safe. If the cardiac biomarkers are positive, NIST with either DSE or MPI 
is recommend (particular attention to whether it has potential to change management), tak-
ing into account specific patient characteristics that would afford benefit from one modality 
when compared to another. If the NIST is positive, then a cardiology consultation should be 
obtained with the appropriate preoperative steps and interventions taken to optimize the 
patient for their procedure. In general, preoperative coronary revascularization has a limited 
role, being reserved for the same indications as in routine circumstances. For the most part, 
chronic CV medications, such as aspirin, ACEI, ARBs and β-blockers, should be continued, 
but the decision should be individualized to each patient’s circumstances. Ideally, thienopyri-
dine antiplatelets therapy should be held before surgery, aside from cases of recent coronary 
stenting, where expert opinion should be sought. Using clinical risk assessment with bio-
markers may decrease further expensive testing and might clarify, optimize risk stratification 
and indicate whether abnormal cardiac biomarker therapies will change outcomes [71, 72].
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